IL10 and Duchenne muscular dystrophy: Furthermore, hDPSC- or IL-10-hDPSC-treated CXMDJ maintained a 15-m running speed and were active at 3 to 12 months of age (Fig. 5b, see also Figure S9, and Table S1; normal vs. control DMD, P < 0.0001–0.0062; control DMD vs. hDPSC-DMD, < 0.005; control DMD vs. IL-10-hDPSC-DMD, < 0.005).